Trials / Unknown
UnknownNCT02981745
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Centaurus Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM). The purpose of the study is to determine the MTD/RP2D of CT-1530, and evaluate its safety and tolerability as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).
Conditions
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom's Macroglobulinemia
- Mantle Zone Lymphoma Refractory/Recurrent
- Follicle Centre Lymphoma Diffuse
- Diffuse Large B Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-1530 | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma |
Timeline
- Start date
- 2017-04-01
- Primary completion
- 2018-09-01
- Completion
- 2018-12-01
- First posted
- 2016-12-05
- Last updated
- 2017-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02981745. Inclusion in this directory is not an endorsement.